AGM Statement
Uniphar plc reported strong performance in 2025, achieving approximately 9% organic gross profit growth and 21% adjusted EPS growth, exceeding expectations due to robust trading, lower finance costs, and a €35 million share buy-back program. The company maintains a healthy liquidity position with Net Bank Debt/EBITDA at 1.6x and has delivered a 16% EPS CAGR over six years, remaining confident in reaching its €200 million EBITDA target by 2028, with at least 80% organic growth. The first four months of 2026 have started well, aligning with board expectations, and Uniphar continues to pursue its growth strategy through organic expansion and disciplined M&A, while prioritizing sustainability.
Select text to share a quote on X · sign in to keep highlights & notes in your UPR notes
| Dublin, London | Thursday, 07 May 2026 |
Uniphar plc (the "Company" or "Uniphar") is holding its AGM today at 11am BST at the office of William Fry, LLP, 6th Floor, 2 Grand Canal Square, Dublin 2, D02 A342, Ireland.
At the AGM, Maurice Pratt, Chairman of Uniphar, will make the following statement:
"I am pleased to report that 2025 was another great year for Uniphar, with the business achieving its fastest rate of organic growth since IPO, with ca. 9% organic gross profit growth. This reinforces the success of our strategy in enhancing our ability to scale the company organically. With each of our three divisions delivering a strong performance, the business achieved 21% adjusted EPS growth in 2025, ahead of the Group's expectations. This was driven by a strong trading performance, lower finance costs and accretion from the €35m share buy-back programme completed in the period.
The Group continues to maintain a strong liquidity position, with Net Bank Debt/EBITDA of 1.6x at year end. We have now delivered a significant 6-year EPS CAGR of 16%, and we remain confident of reaching our €200m EBITDA target by 2028, with at least 80% of our growth being organic.
I am happy to report that 2026 has started well, with performance in the first four months in line with the Board's expectations. Uniphar remains well positioned to deliver organic gross profit growth across each division in line with previous guidance and to deliver on expectations for the full year.
M&A continues to play an important role in Uniphar's growth strategy, and the Group maintains a disciplined approach to capital allocation, while managing an active pipeline of acquisition opportunities to further enhance the Group's growth potential.
Sustainability remains a key priority for the Group and shapes how the business operates day-to-day. Based on
our recent double materiality assessment, we have a clear focus across the Environment, Social and
Governance themes and continue to make good progress.
Finally, as I retire as Chairman this year, I would like to thank our shareholders for their consistent support over the years. I'd also like to express my pride in what the Uniphar team - management, fellow Directors and all our global colleagues - have achieved thus far. I have every confidence that they will continue to grow the business, constantly finding innovative ways to enhance the services we offer to our healthcare clients and their patients."
Uniphar Pharma
Uniphar Pharma operates a global business with high value services across the lifecycle of a pharmaceutical product. We enable pharma and biotech companies to bring innovative medicines to global markets and provide healthcare professionals with access to medicines they cannot source through traditional channels. Our strategy is to build a leading platform to provide the specialist support and expertise needed to improve access to these medicines.
Uniphar Medtech
Uniphar Supply Chain & Retail
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.